MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease

S. Kaneko, S. Morise, R. Tohge, M. Oki, M. Nakamura, N. Takenouchi, H. Kusaka (Hirakata, Japan)

Meeting: 2019 International Congress

Abstract Number: 922

Keywords: Dyskinesias

Session Information

Date: Tuesday, September 24, 2019

Session Title: Parkinsonisms and Parkinson-Plus

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To investigate the difference in results according to the mode of levodopa administration and the effect of zonisamide (ZNS) on striatal cholinergic system, we analyzed the mRNA expression of striatal acetylcholine receptors in a rat model of Parkinson’s disease (PD) in relation to the development of levodopa-induced dyskinesia (LID).

Background: Striatal cholinergic interneurons strongly influence motor function and basal ganglia output. We have previously reported [1] that intermittent levodopa treatment on unilateral PD model rats developed LID, and striatal adenosine A2A receptor mRNA expression was elevated. However, co-administration of ZNS ameliorated the development of LID and inhibited up-regulation of A2A receptors.

Method: Unilateral PD model rats were made by stereotaxic injection of 6-OHDA into the unilateral medial forebrain bundle. These rats were subdivided into four groups and treated as follows; 1) no medication (group N), 2) continuous levodopa infusion (group C), 3) intermittent levodopa injection (group I), 4) intermittent levodopa and ZNS injection (group Z). Two weeks after the treatment, the severity of LID was evaluated, and the expression of striatal mRNAs for muscarinic M1 (Chrm1) and M4 (Chrm1) receptors and nicotinic alpha 7 (Chrna7) and beta 2 (Chrnb2) subunits were analyzed by real-time RT-PCR.

Results: LID was not observed in group C, but was found in group I. Group Z also developed LID, but the dyskinesia in it was less severe than that in group I. Expression of mRNAs for Chrm1, Chrm4, Chrna7 and Chrnb2 was not changed in group N, C, and I. On the other hand, expression of mRNAs for these cholinergic receptors were all reduced in group Z.

Conclusion: ZNS may ameliorate LID through decreasing mRNAs for striatal cholinergic receptors.

References: [1] Oki M, Kaneko S, Morise S, Takenouchi N, Hashizume T, Tsuge A, Nakamura M, Wate R, Kusaka H. Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats. Neurosci Res 122:45-50, 2017

To cite this abstract in AMA style:

S. Kaneko, S. Morise, R. Tohge, M. Oki, M. Nakamura, N. Takenouchi, H. Kusaka. Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/zonisamide-ameliorates-levodopa-induced-dyskinesia-via-striatal-cholinergic-system-in-a-rat-model-of-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/zonisamide-ameliorates-levodopa-induced-dyskinesia-via-striatal-cholinergic-system-in-a-rat-model-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley